6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Shi-Zhen-An-Shen Decoction, a Herbal Medicine That Reverses Cuprizone-Induced Demyelination and Behavioral Deficits in Mice Independent of the Neuregulin-1 Pathway

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Shi-Zhen-An-Shen decoction (SZASD), a Chinese herbal medicine that is a liquor extracted from plants by boiling, has been reported to be effective in treating schizophrenia. However, the mechanism is unclear. Abnormal demyelination has been implicated in schizophrenia. The aim of this study was to investigate the effect of SZASD on myelin in demyelinated mice exhibiting schizophrenia-like behaviors. Sixty male C57BL/6 mice were randomly divided into six groups ( n = 10 per group): (1) control group, (2) cuprizone (CPZ, a copper chelator that induced demyelination, 0.2% w/ w)+saline, (3) CPZ+low-dose SZASD (8.65 g·kg −1·d −1), (4) CPZ+medium-dose SZASD (17.29 g·kg −1·d −1), (5) CPZ+high-dose SZASD (25.94 g·kg −1·d −1), and (6) CPZ+quetiapine (QTP, an atypical antipsychotic that served as a positive treatment control, 10 mg·kg −1·d −1). Mice in groups 2-6 were treated with CPZ added to rodent chow for six weeks to induce demyelination. During the last two weeks, these mice were given an oral gavage of sterile saline, SZASD, or quetiapine. Behavioral tests and brain analyses were conducted after the last treatment. The brain expression of myelin basic protein (MBP) and neuregulin-1 (NRG-1) was assessed using immunohistochemistry and Western blots. CPZ induced significant schizophrenia-like behaviors in the mice, including reduced nest-building activity and sensory gating deficits. Hyperlocomotor activity was accompanied by significant reductions in MBP expression in the corpus callosum, hippocampus, and cerebral cortex. However, both QTP and SZASD significantly reversed the schizophrenia-like behaviors and demyelination in CPZ-fed mice. The QTP and medium-dose SZASD resulted in better therapeutic effects compared to the low and high SZASD doses. Reduced NRG-1 expression was observed in CPZ-fed mice compared with controls, but neither QTP nor SZASD showed significant influence on NRG-1 expression in the hippocampus. Together, SZASD showed a therapeutic effect on demyelinated mice, and the improvement of demyelination might not be through the NRG-1 pathway.

          Related collections

          Most cited references66

          • Record: found
          • Abstract: found
          • Article: not found

          Prevalence of mental disorders in China: a cross-sectional epidemiological study

          The China Mental Health Survey was set up in 2012 to do a nationally representative survey with consistent methodology to investigate the prevalence of mental disorders and service use, and to analyse their social and psychological risk factors or correlates in China. This paper reports the prevalence findings.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Rethinking schizophrenia.

            How will we view schizophrenia in 2030? Schizophrenia today is a chronic, frequently disabling mental disorder that affects about one per cent of the world's population. After a century of studying schizophrenia, the cause of the disorder remains unknown. Treatments, especially pharmacological treatments, have been in wide use for nearly half a century, yet there is little evidence that these treatments have substantially improved outcomes for most people with schizophrenia. These current unsatisfactory outcomes may change as we approach schizophrenia as a neurodevelopmental disorder with psychosis as a late, potentially preventable stage of the illness. This 'rethinking' of schizophrenia as a neurodevelopmental disorder, which is profoundly different from the way we have seen this illness for the past century, yields new hope for prevention and cure over the next two decades.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Animal models of schizophrenia.

              Developing reliable, predictive animal models for complex psychiatric disorders, such as schizophrenia, is essential to increase our understanding of the neurobiological basis of the disorder and for the development of novel drugs with improved therapeutic efficacy. All available animal models of schizophrenia fit into four different induction categories: developmental, drug-induced, lesion or genetic manipulation, and the best characterized examples of each type are reviewed herein. Most rodent models have behavioural phenotype changes that resemble 'positive-like' symptoms of schizophrenia, probably reflecting altered mesolimbic dopamine function, but fewer models also show altered social interaction, and learning and memory impairment, analogous to negative and cognitive symptoms of schizophrenia respectively. The negative and cognitive impairments in schizophrenia are resistant to treatment with current antipsychotics, even after remission of the psychosis, which limits their therapeutic efficacy. The MATRICS initiative developed a consensus on the core cognitive deficits of schizophrenic patients, and recommended a standardized test battery to evaluate them. More recently, work has begun to identify specific rodent behavioural tasks with translational relevance to specific cognitive domains affected in schizophrenia, and where available this review focuses on reporting the effect of current and potential antipsychotics on these tasks. The review also highlights the need to develop more comprehensive animal models that more adequately replicate deficits in negative and cognitive symptoms. Increasing information on the neurochemical and structural CNS changes accompanying each model will also help assess treatments that prevent the development of schizophrenia rather than treating the symptoms, another pivotal change required to enable new more effective therapeutic strategies to be developed. © 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.
                Bookmark

                Author and article information

                Contributors
                Journal
                Neural Plast
                Neural Plast
                np
                Neural Plasticity
                Hindawi
                2090-5904
                1687-5443
                2021
                25 February 2021
                : 2021
                : 8812362
                Affiliations
                1The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China
                2Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China
                3The Affiliated Hospital and the 2nd Clinical Medical College of North Sichuan Medical University, Nanchong Central Hospital, Nanchong 637000, China
                Author notes

                Academic Editor: Massimo Grilli

                Author information
                https://orcid.org/0000-0003-3930-9358
                https://orcid.org/0000-0003-4461-3020
                https://orcid.org/0000-0002-0775-8696
                https://orcid.org/0000-0002-0924-3530
                https://orcid.org/0000-0002-8400-082X
                https://orcid.org/0000-0002-6396-1031
                https://orcid.org/0000-0002-6442-5871
                https://orcid.org/0000-0002-6439-522X
                https://orcid.org/0000-0002-4706-3063
                https://orcid.org/0000-0003-1062-2009
                https://orcid.org/0000-0002-4924-1388
                Article
                10.1155/2021/8812362
                7932787
                33708250
                31e2af66-70ed-43ce-948f-1aa0c194f1e4
                Copyright © 2021 Chao Ma et al.

                This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 15 July 2020
                : 15 January 2021
                : 6 February 2021
                Funding
                Funded by: Beijing Hospital Authority
                Award ID: DFL20191901
                Funded by: Chinese Medicine Science and Technology Development Fund of Beijing
                Award ID: 2018-27
                Funded by: National Natural Science Foundation of China
                Award ID: 81801339
                Award ID: 81873398
                Funded by: Capital's Funds for Health Improvement and Research
                Award ID: 2018-1-2122
                Award ID: 2020-4-2126
                Funded by: Beijing Hospitals Authority Clinical Medicine Development of Special Funding
                Award ID: ZYLX202129
                Categories
                Research Article

                Neurosciences
                Neurosciences

                Comments

                Comment on this article